COVID 19 Nucleocapsid (Np) Humanized Coronavirus (COVID-19) Antibody – Monoclonal

The 2019 novel coronavirus, abbreviated as 2019-ncov, is a new strain of coronavirus discovered in the human body in 2019. The symptoms of the virus are fever, fatigue, dry cough, and progressive dyspnea. In severe cases, the symptoms are acute respiratory distress syndrome, septic shock, metabolic acidosis and coagulation dysfunction that can’t be corrected. The virus has been confirmed to exist the phenomenon of human-to-human transmission, the shortest incubation period of the virus is only 1 day, and the longest incubation period is 14 days. The patients in incubation period is contagious and there is no specific treatment for the disease. . After a human is infected with a new virus for the first time, the body's immune system will immune-defend the virus and produce specific antibodies. Generally, IgM antibody will appear in 1-2 weeks and IgG antibody will appear in 4 weeks.

Kasetsirikul S, N. Umer N, S.K Soda, M.J.A Rajan, A Shiddiky, N Nguyen. Detection of SARS-CoV-2 humanized antibody with paper-based ELISA. Analyst, 2020, DOI: 10.1039/D0AN01609H. Recombinant SARS-CoV-2 nucleocapsid (MBS355892) and SARS-CoV-2 nucleocapsid humanized antibody (MBS355887) were used for a paper-based ELISA assay. Figures 1-5, Table I. Recombinant SARS-CoV-2 nucleocapsid (MBS355892) was used as antigen and the SARS-CoV-2 nucleocapsid humanized antibody (MBS355887) was used as a positive control in the paper-based ELISA.

Small volumes of anti-COVID-19 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MBS355887 is an antibody targeting COVID-19. Also known as Anti-SARS-CoV-2 Nucleocapsid / COVID-19, Humanized antibody. Reactive in Human. Host: Cultured in vitro.